Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia

Inclusion Criteria: Adults (age\> 15 years) with ALL standard risk previously untreated. The LAL standard risk is defined by all of the following criteria: * Age less than 30 years * WBC \<25x109 / L * Absence of cytogenetic alterations that misbehave forecast or t (9, 22) or demonstration of BCR-ABL rearrangement or alterations in 11q23, or demonstration ALL1-AF4 rearrangement (MLL) Exclusion Criteria: LAL L3 type mature phenotype B (sIg +) or with cytogenetic abnormalities characteristic of Burkitt LAL (t \[8, 14\], t \[2, 8\], t \[8, 22\]). For these patients have the BURKIMAB study. * LAL Ph (BCR-ABL) positive. These patients should be treated with imatinib associated with chemotherapy. * Biphenotypic acute leukemias and bilinear. For these patients treatment is recommended LAM own guidelines. * Acute undifferentiated leukemias. For these patients treatment is recommended LAM own guidelines. * Patients with a history of coronary artery disease, valvular or hypertensive heart disease. * Patients with chronic liver disease. * Patients with chronic respiratory failure. * Renal failure not due to the LAL. * Severe neurological disorders, not due to the LAL. * General State concerned (grades 3 and 4 WHO scale), not attributable to the LAL.